NEW YORK (Reuters Health)—Rheumatoid arthritis patients with depression and anxiety symptoms may have worse outcomes and poorer response to prednisolone, a secondary analysis of the CARDERA trial has found. “The strength of association between depression/anxiety and disease activity outcomes and treatment response warrants routine screening,” the study’s lead author Faith Matcham at King’s College London…
Can We Get Closer to a Cure for RA?
Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.
Brentuximab Vedotin Enters Phase 2 Trials & More
Phase 2 clinical trials have begun to assess the safety of brentuximab vedotin for the treatment of SLE. Also, the FDA is reviewing an application for a once-daily tofacitinib citrate tablet to treat RA…
Family History Not Linked to Clinical Presentation, Treatment Response of RA
NEW YORK (Reuters Health)—Having a family history of rheumatoid arthritis (RA) does not appear to influence the clinical presentation or treatment response of RA to standard medications, researchers from Sweden report. “At first we were a bit surprised by our findings,” Dr. Thomas Frisell from Karolinska Institutet in Stockholm told Reuters Health by email. “Patients…
Nurses May Be Key to Long-Term Clinical Trial Success
After completing a 10-year clinical trial examining treatment strategies for rheumatoid arthritis, Dutch researchers used a questionnaire to determine the study conditions and individual motivators that kept 60% of patients participating long term…
Ixekizumab Clinical Trials Continue; FDA Updates Warning Label for Varenicline
It seems to have begun in Norway, the international pressure to switch patients from well-known brand biologic agents, such as Remicade (infliximab), to biosimilar agents, due to a significant cost advantage.1 This biosimilar came with a 39% price markdown last year compared with the brand, and when Norway called for bids, the discount went to…
An Identity Crisis for RA
A few suggestions to bring rheumatic disease the recognition and respect it deserves
Pain Management for the Person with RA: An Occupational Therapist’s Perspective
RA is a chronic disease that people must learn to live with for their lifetime. Occupational therapists (OTs) play a pivotal role in assisting patients with RA with functioning in the face of a disease that causes limitations and deformities.
How Energy Shifts Lead to Systemic Illness
The impact of adaptive energy programs on the manifestations of chronic inflammatory disease
Russians Mourn Iconic Rheumatologist
Valentina A. Nasonova, MD, was Renaissance figure in Russian rheumatology
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- 30
- Next Page »